Hospital Pierre Wertheimer — Clinical Trial Site

25 Registered trials

10 Currently recruiting

Organisation

Hospital Pierre Wertheimer

Location

Bron, France

Identifier

ORG-100030301

Address

59 Boulevard Pinel, 69500, France

Departments

#1000:Service de neuro-oncologie
Anesthésie Réanimation
Département neurologie
Department of Functional Neurology and Epileptology
Functional Neurology and Epileptology
n/a
Neuro Oncology
Neurologie
Neurology
Neurology Department
Rhône
Service de Neuro-Oncologie
Service de Neurologie
Service de Neurologie C, Pr E. Broussolle
Service de neurologie, sclérose en plaques, pathologies de la myéline et neuroinflammation
Service de neuropsychologie
Service Neurologie

Clinical trials at this site (25)

Search interface

A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting

2022-502286-16-00 Primary Generalized Tonic-Clonic Seizures 5 2023-10-27
The effect of amantadine as add-on therapy for motor fluctuations in advanced Parkinson’s disease: a randomized double-blinded placebo-contr… Recruiting

2023-509728-16-00 advanced Parkinson’s disease 4 2025-10-10
Efficacy of daily IV administration of dornase alfa for up to 14 days post subarachnoid haemorrhage on functional independence at 6 months: … Recruiting

2023-509627-40-01 subarachnoid hemorrhage 5 2025-05-15
Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub… Recruiting

2024-510893-25-00 Brain metastases of cancer > brain radionecrosis 5 2025-04-29
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting

2023-507351-29-00 Alzheimer's Disease Psychosis 5 2024-12-03
CAPSAPED Recruiting

2022-500265-27-00 Chronic postchirurgical or post-traumatic neuropathic p 5 2024-03-05
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 5 2024-02-14
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting

2022-502281-25-00 Focal Onset Seizures 5 2023-09-27
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients … Recruiting

2022-501822-39-00 Glioblastoma 9 2023-07-31
Efficacy and Safety Study of Nipocalimab for Adults with CIDP Recruiting

2023-508425-28-00 Chronic Inflammatory Demyelinating Polyneuropathy 4 2022-10-24
Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) Ended

2024-511452-40-00 Oncology - Glioblastoma (GBM) 10 2025-09-12
ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended

2023-507325-42-00 Alzheimer Disease psychosis 4 2024-07-02
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Myelin Oligodendrocyte Gly… Ended

2023-507196-22-00 Myelin Oligodendrocyte Glycoprotein Antibody-Associated 5 2022-06-20
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblasto… Ended

2023-506719-17-00 Glioblastoma 3 2022-05-10
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu… Ended

2023-506516-40-00 Relapsing-Remitting Multiple Sclerosis 5 2022-02-11
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson’s Disease (BeyoND) Ended

2024-513548-27-00 Parkinson's disease 4 2016-10-05
A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodec… Ended

2023-505086-83-00 Tourette Syndrome 4 2024-07-10
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to s… Ended

2022-502540-12-00 Refractory Status Epilepticus (RSE) 5 2023-11-09
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep… Ended

2022-503067-15-00 Tuberous Sclerosis Complex (TSC) related epilepsy 5 2023-10-02
A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended

2024-512123-37-00 Parkinson's disease 5 2021-05-27